Roche said its fenebrutinib drug candidate met primary goals in two late-stage trials for multiple sclerosis, reducing attacks or delaying disability progression in two different forms of the disease.

NESS ZIONA, Israel, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting ...

Add Yahoo as a preferred source to see more of our stories on Google. The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020. REUTERS/Arnd Wiegmann/File ...

Roche (OTCQX:RHHBY) shares closed ~4% higher in Europe on Monday as the maker of Ocrevus multiple sclerosis therapy announced two Phase 3 trial successes for fenebrutinib, its new experimental drug ...

Cognitive health is not only the absence of cognitive impairment. It's the ability to maintain mental efficiency, flexibility, and emotional balance despite the burden of the disease. Cognitive ...

BERLIN, Feb 7 (Reuters) - Swiss pharmaceutical company Roche (ROG.S), opens new tab said on Saturday its experimental multiple sclerosis drug fenebrutinib met the main goal in a late-stage trial in ...